BioE Wins 2006 Tekne Award
BioE®, Inc. has announced that it won a 2006 Tekne Award for its "remarkable" stem cell advancements with the company's rare Multi-Lineage Progenitor Cell™ (MLPC™) derived from human umbilical cord blood.
The Tekne selection committee also distinguished BioE for its "smart business model for today's stem cell research technology."
The Minnesota Tekne Awards have been held annually since 2000 and honor companies, innovations and individuals that positively impact Minnesota's technology-based economy.
The Minnesota High Tech Association (MHTA) and Minnesota Technology, Inc., in partnership with LifeScience Alley, present the Tekne Awards. BioE was recognized in the "Emerging Biotechnology" category.
"Because our state is privileged to serve as a home to many leading high-tech companies, it's an honor to be singled out and named a Tekne Award winner," said Kate Rubin, president of MHTA.
"We are proud to acknowledge BioE for its exciting work with cord blood stem cells, and look forward to seeing the company continue to grow and help further establish Minnesota as a national and global hotbed of scientific discovery and innovation."
The MLPC is a stem cell that was discovered and commercialized by BioE and has shown the capacity to turn into multiple cell and tissue types - including neural stem cells, nerve cells, lung cells, early stage liver and pancreas cells, skeletal muscle, fat cells, bone cells, and blood vessels.
Since July 2005, BioE has licensed its MLPC to 80 academic research institutions, corporate laboratories and pharmaceutical organizations located around the world for stem cell and regenerative medicine research and drug development.
"We are thrilled to receive a 2006 Tekne Award," said Michael Haider, president and chief executive officer for BioE.
"The stem cell industry is rapidly taking shape and recognition like this helps further solidify our burgeoning leadership position."
"We've had a banner year already in 2006 thanks to the tremendous efforts of our employees, research collaborators and partners."
"Next year also looks very promising, as we continue to take ownership of an entirely new category of highly functional cord blood stem cells and capitalize on a variety of diverse business opportunities."